The latest update is out from Windtree Therapeutics ( (WINT) ).
On April 19, 2025, Windtree Therapeutics, through its subsidiary WINT Real Estate, LLC, entered into an Assignment and Conditional Assumption Agreement with Way Maker Growth Fund, LLC to acquire a multifamily residential property in Houston, Texas. This strategic move is part of Windtree’s plan to generate consistent rental revenue while continuing to develop its therapeutic pipeline. The acquisition is expected to be funded primarily through non-recourse secured mortgage financing, supplemented by proceeds from the issuance of preferred stock. Additionally, on April 29, 2025, Windtree completed a Securities Purchase Agreement for a private placement of Series D Convertible Preferred Stock, raising approximately $2.5 million. This financial maneuver is aimed at supporting the company’s strategy to diversify revenue sources and stabilize its operations, reducing reliance on potentially dilutive capital.
Spark’s Take on WINT Stock
According to Spark, TipRanks’ AI Analyst, WINT is a Underperform.
Windtree Therapeutics faces significant financial challenges with no revenue and considerable net losses, severely impacting its financial health and stability in the biotechnology sector. The technical analysis suggests bearish momentum, aligning with the weak financials. The negative P/E ratio and lack of dividends make valuation unattractive. Overall, the stock presents considerable risks, with limited upside potential without a substantial change in financial performance or market conditions.
To see Spark’s full report on WINT stock, click here.
More about Windtree Therapeutics
Windtree Therapeutics, Inc. is a biotechnology company focused on becoming a revenue-generating biotech and advancing early and late-stage innovative therapies for critical conditions and diseases. Windtree’s portfolio includes istaroxime, a Phase 2 candidate for acute heart failure and cardiogenic shock, preclinical SERCA2a activators for heart failure, and preclinical precision aPKCi inhibitors for oncology applications. The company also has a licensing business model with partnership out-licenses.
YTD Price Performance: -93.30%
Average Trading Volume: 2,890,343
Technical Sentiment Signal: Buy
Current Market Cap: $4.27M
See more data about WINT stock on TipRanks’ Stock Analysis page.